Literature DB >> 18222013

Gallbladder disease in patients with primary sclerosing cholangitis.

Karouk Said1, Hans Glaumann, Annika Bergquist.   

Abstract

BACKGROUND/AIMS: Gallbladder abnormalities may be part of the spectrum in primary sclerosing cholangitis (PSC). The aim of the present study was to evaluate the occurrence and prognostic importance of gallbladder abnormalities in patients with PSC.
METHODS: Presence of gallbladder abnormalities was assessed in 286 patients with PSC treated at the Liver Unit, Karolinska University Hospital, Huddinge, between 1970 and 2005.
RESULTS: One or more gallbladder abnormalities were found in 41% of the patients. Gallstones were found in 25% and cholecystitis in 25%. Cholecystitis among patients with extrahepatic involvement of PSC (30% (65/214)) was significantly higher than among those with intrahepatic involvement (9% (6/70)) (P<0.0001). A gallbladder mass lesion with a mean size of 21 (+/-9) mm (S.D.) was found in 18 (6%) patients, in 56% (10/18) of whom it constituted gallbladder carcinoma. In 9 patients without a gallbladder mass lesion, histological re-evaluation disclosed epithelial dysplasia of the gallbladder.
CONCLUSIONS: Gallbladder disease is common in patients with PSC. Dysplasia and carcinoma are commonly found in gallbladder epithelium, suggesting that regular examination of the gallbladder in PSC patients could be of value for early detection of a gallbladder mass lesion. Cholecystectomy is recommended when such a lesion is detected, regardless of its size.

Entities:  

Mesh:

Year:  2008        PMID: 18222013     DOI: 10.1016/j.jhep.2007.11.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  42 in total

1.  Answers to multiple choice questions.

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-12

2.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

3.  38-year-old woman with abnormal liver enzymes and hyperlipidemia.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Mayo Clin Proc       Date:  2009-06       Impact factor: 7.616

Review 4.  Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Authors:  Mai Sedki; Cynthia Levy
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

5.  Xanthogranulomatous cholecystitis complicated with primary sclerosing cholangitis: report of a case.

Authors:  Akira Mori; Ryuichiro Doi; Yoshikuni Yonenaga; Shuichiro Nakabo; Shujiro Yazumi; Junya Nakaya; Fumihiko Kono; Toshiaki Manabe; Shinji Uemoto
Journal:  Surg Today       Date:  2010-07-30       Impact factor: 2.549

6.  The value of thioredoxin family proteins and proliferation markers in dysplastic and malignant gallbladders in patients with primary sclerosing cholangitis.

Authors:  Karouk Said; Hans Glaumann; Mikael Björnstedt; Annika Bergquist
Journal:  Dig Dis Sci       Date:  2012-02-28       Impact factor: 3.199

Review 7.  Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.

Authors:  Rosy Wang; Rupert W Leong
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 8.  The inflammatory inception of gallbladder cancer.

Authors:  Jaime A Espinoza; Carolina Bizama; Patricia García; Catterina Ferreccio; Milind Javle; Juan F Miquel; Jill Koshiol; Juan C Roa
Journal:  Biochim Biophys Acta       Date:  2016-03-12

Review 9.  Screening for malignancy in primary sclerosing cholangitis (PSC).

Authors:  Saira A Khaderi; Norman L Sussman
Journal:  Curr Gastroenterol Rep       Date:  2015-04

Review 10.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.